Stockscreener 앱 받기
4.87
2.31%
0.11
시간 외 거래:
4.87
전일 마감가:
$4.76
열려 있는:
$4.82
하루 거래량:
242.43K
Relative Volume:
0.62
시가총액:
$282.18M
수익:
-
순이익/손실:
$-68.46M
주가수익비율:
-3.6617
EPS:
-1.33
순현금흐름:
$-57.37M
1주 성능:
-0.61%
1개월 성능:
+9.68%
6개월 성능:
+4.96%
1년 성능:
+412.58%
1일 변동 폭
$4.71
$4.93
1주일 범위
$4.47
$4.98
52주 변동 폭
$0.9199
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
명칭
Rezolute Inc
전화
650-206-4507
주소
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
RZLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.87 | 282.18M | 0 | -68.46M | -57.37M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-08-27 | 개시 | Guggenheim | Buy |
| 2024-07-17 | 개시 | BTIG Research | Buy |
| 2024-06-04 | 개시 | Craig Hallum | Buy |
| 2024-04-09 | 개시 | Maxim Group | Buy |
| 2022-08-02 | 재개 | Canaccord Genuity | Buy |
| 2022-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-09-08 | 개시 | ROTH Capital | Buy |
| 2021-05-27 | 개시 | Oppenheimer | Outperform |
| 2021-05-25 | 개시 | H.C. Wainwright | Buy |
모두보기
Rezolute Inc 주식(RZLT)의 최신 뉴스
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
State Street Corp Acquires 13,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) - Defense World
MML Investors Services LLC Makes New $57,000 Investment in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying - Yahoo Finance
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Target Price at $24.13 - Defense World
Rezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by Analysts - MarketBeat
Rezolute CFO Daron Evans buys $42,900 in company stock By Investing.com - Investing.com Australia
Rezolute CFO Daron Evans buys $42,900 in company stock - Investing.com India
Insider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of Stock - MarketBeat
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential - Investing.com Nigeria
Rezolute's SWOT analysis: biotech stock's pipeline progress and market potential By Investing.com - Investing.com South Africa
Chief Financial Officer of Rezolute Daron Evans Buys 6.5% More Shares - Simply Wall St
Rezolute (NASDAQ:RZLT) and BetterLife Pharma (OTCMKTS:PVOTF) Head to Head Comparison - Defense World
When the Price of (RZLT) Talks, People Listen - Stock Traders Daily
Rezolute expands authorized shares following shareholder approval - Investing.com
Daron Evans, CFO of Rezolute, buys $53,166 in common shares By Investing.com - Investing.com Nigeria
Daron Evans, CFO of Rezolute, buys $53,166 in common shares - Investing.com
RZLT Stock Rises on FDA's Orphan Designation for Rare Disease Drug - MSN
Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Rezolute Grants 150,000-Share Inducement Award to New Supply Chain Executive - StockTitan
Rezolute retains steady stock target on Orphan Drug nod By Investing.com - Investing.com Canada
RZLT Stock Rises On FDA's Orphan Designation For Rare Disease Drug - Barchart
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - Marketscreener.com
Rezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism Market (NASDAQ:RZLT) - Seeking Alpha
Rezolute Receives Orphan-Drug Designation from FDA for Low Blood Sugar Treatment - MarketWatch
FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
Rezolute's Hypoglycemia Drug Wins FDA Orphan Drug Status; Phase 3 Trial Set for 2025 - StockTitan
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Price Target from Analysts - MarketBeat
Rezolute, Inc. Advances Late-Stage Trials for Rare Disease Therapies - TipRanks
BTIG Initiates Coverage of Rezolute (RZLT) with Buy Recommendation - MSN
Rezolute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2024 - Marketscreener.com
Wedbush Initiates Coverage of Rezolute (RZLT) with Outperform Recommendation - MSN
Institutional investors in Rezolute, Inc. (NASDAQ:RZLT) lost 11% last week but have reaped the benefits of longer-term growth - Simply Wall St
Is Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Rezolute Inc (RZLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):